A phase 1, randomized, observer blind, antigen and adjuvant dosage finding clinical trial to evaluate the safety and immunogenicity of an adjuvanted, trivalent subunit influenza vaccine in adults  ≥ 65 years of age.

CONCLUSION: In this phase I trial of adults ≥ 65 years of age who received increased adjuvant and antigen dosages relative to the licensed aTIV, increased dosage of MF59 resulted in increased immunogenicity against all 3 components of seasonal influenza vaccine. The increase in immunogenicity was accompanied by an increase in the incidence of local reactogenicity. PMID: 31679865 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31679865?dopt=Abstract

Source: Vaccine - October 30, 2019 Category: Allergy & Immunology Authors: Otten G, Matassa V, Ciarlet M, Leav B Tags: Vaccine Source Type: research

A phase 1, randomized, observer blind, antigen and adjuvant dosage finding clinical trial to evaluate the safety and immunogenicity of an adjuvanted, trivalent subunit influenza vaccine in adults ≥ 65 years of age.

A phase 1, randomized, observer blind, antigen and adjuvant dosage finding clinical trial to evaluate the safety and immunogenicity of an adjuvanted, trivalent subunit influenza vaccine in adults  ≥ 65 years of age.